Health Blueprint

Masters of Longevity - The Pulse

Feature20 Oct 2026

MOTS-c: Where the Evidence Ends

Studies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?

MOTS-c: Where the Evidence Ends

By The Peptide Dosing editorial team

Studies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?

Feature20 Oct 2026
Abstract illustration of mitochondria with folded inner membranes in a cell

Editorial Picks

More from MoL
Conceptual amber glass heart within a translucent teal torso, illustrating an organ within its surrounding body.

How Old Is a Transplanted Heart?

By Marcel Achermann

Science Brief05 Oct 2026

Conceptual biomedical lab scene with AI research-agent panels connecting literature, hypothesis planning and experiment analysis to an automated pipetting station and a scientist at a microscope; not experimental data.

Anthropic’s Claude Phage Finding and the New Pace of Research

By Marcel Achermann

Commentary24 Sept 2026

Three global-health professionals examine a city map and interconnected images of neighbourhoods, services and care settings in a research workspace.

What Global Dementia Risk Models Still Miss

By Marcel Achermann

Science Brief24 Sept 2026

Older woman practising a controlled heel-to-toe balance step beside a sturdy chair at home, with a small unbranded supplement jar on a side table.

Calcium, Vitamin D and Fall Prevention: What the Evidence Changes

By Marcel Achermann

Science Brief22 Sept 2026

Conceptual cross-section of human hippocampal tissue with support cells, microglia-like cells and folded chromatin inside a cell nucleus.

What Changes in the Human Hippocampus with Age?

By Marcel Achermann

Editorial20 Sept 2026

Conceptual glass DNA helix and separate building blocks in a dark laboratory-inspired scene.

Nucleotides and Longevity: Is the Evidence Ready?

By Marcel Achermann

Editorial17 Sept 2026

Trending News

Based on last 48h engagement

  1. 01Gradient-driven microfluidic framework for the screening of ratiometric drug combinations towards precision oncology in paediatric leukaemia (Nature - Biotechn...Gradient-driven microfluidic framework for the screening of ratiometric drug combinations towards precision oncology in paediatric leukaemiaNature - Biotechnology • 23 Oct 2026External link, opens in a new tab
  2. 02Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026 (PR Newswire)Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026PR Newswire • 24 Oct 2026External link, opens in a new tab
  3. 03Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO (PR Newswire)Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMOPR Newswire • 25 Oct 2026External link, opens in a new tab
  4. 04The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneous... (PR Newswire)The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of MedicinePR Newswire • 25 Oct 2026External link, opens in a new tab
  5. 05Personalized medicine comes to cancer immunotherapy (Peter Attia Blog)Personalized medicine comes to cancer immunotherapyPeter Attia Blog • 24 Oct 2026External link, opens in a new tab

Upcoming Events

View calendar
  1. THE LIVE Barcelona 2026 (Barcelona, Spain)26. OCT 2026 - 28. OCT 2026THE LIVE Barcelona 2026Media PartnerSummit - Barcelona, Spain★
  2. CEE Longevity Summit & Retreat 2026 (Samorin, Slovakia)29. OCT 2026 - 31. OCT 2026CEE Longevity Summit & Retreat 2026Retreat - Samorin, Slovakia
  3. Parkhotel Longevity Retreat — October 2026 (Bad Bayersoien, Germany)31. OCT 2026 - 8. NOV 2026Parkhotel Longevity Retreat — October 2026Retreat - Bad Bayersoien, Germany
  4. Biology of Aging Symposium V 2026: The Possibilities of Aging and Health (Montreal, Canada)1. NOV 2026 - 3. NOV 2026Biology of Aging Symposium V 2026: The Possibilities of Aging and HealthConference - Montreal, Canada
  5. Atlas Cove Longevity Residency — November 2026 (Setúbal, Portugal)1. NOV 2026 - 6. NOV 2026Atlas Cove Longevity Residency — November 2026Retreat - Setúbal, Portugal

Latest in Longevity

|←←→
Aging Cell26 Oct 2026
AINonlinear Aging of the Human TCR Repertoire Is Influenced by Sex, CMV, and Cancer (Aging Cell)

Nonlinear Aging of the Human TCR Repertoire Is Influenced by Sex, CMV, and Cancer

Researchers found nonlinear age-related changes in human T cell receptor repertoires influenced by sex, CMV, and cancer.

Key takeaways
  • TCR diversity declines with age but the decline is nonlinear.
  • Sex is associated with different TCR aging trajectories.
  • CMV seropositivity and cancer history are linked to altered TCR aging.
Frontiers - Health26 Oct 2026
AITranslational trends and specific nutritional interventions for aromatase inhibitor induced bone loss based on a 25 year multi database bibliometric and themati

Translational trends and specific nutritional interventions for aromatase inhibitor induced bone loss based on a 25 year multi database bibliometric and thematic evolution analysis from 2000 to 2025

A 25-year bibliometric review mapped nutritional interventions for AIBL.

Key takeaways
  • Aromatase inhibitors are linked to accelerated bone loss.
  • Calcium and vitamin D are used to support bone mineralization.
  • Dietary patterns and gut metabolites were found to affect bone resorption.
Fight Aging!25 Oct 2026
AIFight Aging! Newsletter, October 26th 2026 (Fight Aging!)

Fight Aging! Newsletter, October 26th 2026

An early open-label glaucoma trial reported OSK gene therapy was tolerated through Day 56.

Key takeaways
  • A single eye injection was reported as tolerated through Day 56.
  • Two of three glaucoma participants showed preliminary visual-field gains.
  • These early findings do not establish that the therapy is effective.